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Intraplacental choriocarcinoma is a rare malignant tumor diagnosed after an abortion, an ectopic pregnancy, or a term or preterm
pregnancy or following the diagnosis of a hydatidiform mole. During pregnancy, it may be more common than reported, as most
patients are asymptomatic and placental choriocarcinomas are usually inconspicuous macroscopically and are often mistaken
for an infarct. Based upon a case study methodology, we describe 2 cases of intraplacental choriocarcinoma: the first case was
identified in the product of a uterine curettage following an incomplete miscarriage and the second in one of the placentas of a
bichorionic twin pregnancy. Maternal investigation did not reveal evidence of metastatic disease and neither did the infants’ one in
the second case. The two cases underwent maternal surveillance with serum hCG and remained disease-free until the present. In
conclusion, intraplacental choriocarcinoma is easily underdiagnosed but with current treatment, even in the presence ofmetastasis,
the prognosis is excellent. A routine microscopic examination of all the placentas and products of miscarriage can increase the real
incidence of this entity and consequently improve its management.
1. Introduction
The gestational trophoblastic disease includes a spectrum of
tumors from hydatidiform moles to more malignant forms:
the invasive mole, the placental site, and epithelioid tropho-
blastic tumors and choriocarcinoma. Intraplacental chorio-
carcinoma is a focal neoplastic proliferation of the chorionic
villous trophoblast. It is a rare variant of gestational chorio-
carcinoma but, due to its rareness, the information available
is still limited, with scarce data derived from individual case
reports or small case series (only 62 cases reported in the
literature [1]). It accounts for no more than approximately
0.04% of all gestational trophoblastic diseases [2–4].
However, as the placenta’s histological examination is not
routinely performed and the lesions have an inconspicuous
appearance, the real incidence is probably underestimated
[3]. In some case reports, the diagnosis followed the first
trimester abortions, in others it followed hydatidiformmoles
and preterm or term pregnancies [1, 5, 6], with most cases
identified in the third trimester in asymptomatic women [4].
The aetiology, pathogenesis, natural history, and adequate
therapy of choriocarcinoma are still unknown. The reported
cases in the literature describe different outcomes. In some
cases, the authors describe fatal outcomes associated with
maternal or fetal/infantmetastatic disease (particularly to the
lungs) [6, 7], while in others therewere no implications for the
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Figure 1: Placental histological features from case 1 at 8 weeks of gestational age [(a), (b), and (c)] and case 2 at 32 weeks of gestational age
[(d), (e), and (f)]. Chorionic villi (small arrow) surrounded by tumor trophoblast cells [cytotrophoblast and intermediate trophoblast with
patchy small foci of syncytiotrophoblast (arrow)]. Mitotic figures (head arrow).
mother and infant [8]. Complications as intrauterine growth
restriction, premature birth, fetal anaemia, and transplacental
haemorrhage have also been reported [1–3].
Because this disease is potentially curable and a longer
interval between delivery and treatment adversely affects the
outcome, the early diagnosis is important [7–10].
Treatment trends have also been changing. Formetastatic
disease, the prognosis was very poor before 1980, with the
5 cases reported resulting in maternal death. A few authors
described that the administration of methotrexate alone has
been successful in treating metastases [9, 11]. Hysterectomy
without adjuvant treatment showed to be ineffective but
after starting the treatment with chemotherapy the prognosis
improved dramatically, with a recently reported long term
remission rate of 100% [1]. In nonmetastatic disease, isolated
maternal serum hCG surveillance was recommended in
a recently published management guidance [1]. Additional
surgery or chemotherapy seems to be unnecessary.
The objective of this article is to describe 2 cases of intra-
placental choriocarcinoma diagnosed after a clinical suspi-
cion of an incompletemiscarriage and a preterm spontaneous
vaginal delivery. We reviewed the clinical files of the mothers
diagnosed with intraplacental choriocarcinoma and of their
infants and the study was approved by the Local Research
Ethics Committee.
2. Case Presentation
2.1. Case 1. Primigravida, 29 years old, with no significant
obstetric or medical history, presented with vaginal bleeding
and an 8-week amenorrhea in December 2010.
Physical examination was normal. The ultrasound
showed a placenta with hypoechogenic vesicular formations
with no embryo. The serum hCG level was 141723mUI/mL.
An aspirative curettage was performed. On microscopic
examination, slid sheets of cytotrophoblastic and multi-
nucleated syncytium without stroma were identified (Figures
1(a), 1(b), and 1(c)).
The chest CT scan and the brain MRI showed no metas-
tasis. One month after the curettage, the serum hCG levels
spontaneously returned to normal. The follow-up in the next
2 years, without therapy, was negative.
In December 2012, she had a subsequent pregnancy,
complicated by gestational diabetes. Labourwas induced at 39
weeks and she delivered vaginally a 3470 g female newborn.
The placenta’s histopathological examination had no signs of
intraplacental choriocarcinoma and the serum hCG levels
were negative after birth.The infant had no signs ofmetastatic
disease and remains well.
2.2. Case 2. Primigravida, 29 years old, with no signifi-
cant obstetric or medical history, had an uncomplicated
pregnancy with normal fetal ultrasounds throughout the
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gestation. She spontaneously delivered vaginally, bichorionic
twins at 32 weeks and 5 days, in August 2013. The newborns
weighed 2020 g and 1935 g. They were admitted in the NICU
due to prematurity. The postpartum period was uneventful.
The placentas (fused) had no macroscopically visible lesions
but were sent to routine histological examination due to the
preterm delivery.
The placenta corresponding to the first twin was 19 × 10 ×
3 cm and the microscopic examination showed an intrapla-
cental choriocarcinoma characterized by focal proliferation
of both cytotrophoblast and syncytiotrophoblast in the inter-
villous space without involvement of the adjacent chorionic
villi (Figures 1(d), 1(e), and 1(f)). There was no invasion
of the stromal or vascular tissues. The maternal physical
examination, ultrasound, serum hCG levels, chest CT scan,
and brain MRI were normal one month after the delivery.
The follow-up is negative until the present with only hCG
surveillance. Both mother and infants have been disease-free
for 3 years.
3. Discussion
Intraplacental choriocarcinoma is a rarely reported malig-
nant tumor that arises from chorionic villous trophoblast.
The majority of the cases reported in the literature follow the
diagnosis of a hydatidiform mole [1, 2], but they can follow
an otherwise normal nonmolar placenta. The first report was
in 1963 when Driscoll described an “incidental finding of a
choriocarcinoma within a term placenta” [12]. Fukunaga and
Nomura also defined it as a “neoplastic trophoblast prolif-
eration localized on the placenta that implies the absence of
metastases” [8]. However, other authors described associated
maternal or fetal metastatic lesions, particularly to the lungs,
that may be fatal to both. Occasionally, a tumor in the
placenta is not identified despite metastasis in the neonate. In
some of these cases, this was certainly due to the lack of
placental examination. Massive transplacental fetal haemor-
rhage has also been reported [3, 5, 6, 9, 10]. Thus, some
authors consider it more accurate to use the term “intrapla-
cental choriocarcinoma” because of this possibility of distant
metastases.
The prevalence of choriocarcinoma is low but it is most
often seen in women aged less than 15 or more than 45 years
old, as well as inmultiparouswomen [2, 3, 5]. However, due to
the subtle nature of the gross appearance of these lesions, it is
likely that many cases go undiagnosed and the real incidence
is higher than documented.
The aetiology and pathogenesis of the lesions are still
unknown [1–5, 10, 11].
Prenatal diagnosis of this entity is rarely possible and
inconsistent but a mass lesion can be found. The maternal
symptoms,when present, are also nonspecific.Themost com-
mon presentation is the vaginal bleeding but the symptoms
related to metastasis like haemoptysis or cough have been
reported [1, 3, 11]. However, in the majority of the cases,
the disease is clinically silent and the diagnosis is based
on the pathological placental or RPOC examination. Fetal
and obstetric reported complications include fetomaternal
haemorrhage, placental abruption, fetal hydrops, anaemia,
intrauterine growth restriction, and fetal death [1, 2, 5, 9, 12].
In our first case, vaginal bleeding was the symptom that led
the woman to the hospital. The second case was diagnosed
incidentally in one of the placentas of a twin pregnancy
when the placenta was examined due to a preterm delivery.
The mother had no symptoms and there were no fetal
complications related to the tumor.
Regarding the pathological findings, usually the lesions
are not macroscopically visible or have an inconspicuous
appearance, being often mistaken for an infarct [6, 8, 9].
Liu and Guo reviewed the different gross appearance of the
lesions and identified single or multiple nodules similar to
infarctions [13]. Microscopically, the focal proliferation of
both cyto- and syncytiotrophoblast (biphasic) in the stemvilli
that project to the intervillous space, with significant necrosis
in the centre, is the typical pattern. Some reports describe
stromal or vascular invasion [6, 8, 9]. In both our cases, there
was microscopic proliferation of both cytotrophoblast and
syncytiotrophoblast, occupying the intervillous spacewith no
stromal or vascular invasion.
Detailed maternal physical examination, serum hCG,
X-ray, ultrasound, CT scan, and MRI should always be
performed to rule out metastasis when a choriocarcinoma
in situ is suspected or confirmed because clinical outcomes
appear to depend on the presence of metastasis [1, 2, 5, 7, 9,
10, 13, 14].
The optimal treatment of intraplacental choriocarcinoma
is still unclear. According to one review in 2003, before
chemotherapy was available, the overall survival at 5 years
for choriocarcinoma with hysterectomy alone was 41% in
the absence of metastases and 19% in the metastatic cases.
Chemotherapy increased survival to almost 100% [9]. How-
ever, treatment of nonmetastatic disease is controversial.
Some authors describe cases of success with only surveillance
[1, 3, 8, 14, 15]. Some authors suggested that “patients with
choriocarcinoma confined to the placentawith rapid decrease
of serum hCG after the removal of the placenta do not
need chemotherapy, but only fetal and maternal close follow-
up” [16]. In a recent review and management guidance
published in 2016, only surveillance in cases of nonmetastatic
disease is also recommended [1]. In our cases, there were no
signs of dissemination and serum hCG decreased rapidly, so
the women were not treated with chemotherapy and were
kept under surveillance with beta-HCG and imaging, with
negative follow-up until now. In the first case, the womanwas
pregnant after 3 years and had no complications or signs of
the disease.
In conclusion, intraplacental choriocarcinomamay man-
ifest as a spectrum of clinical entities ranging from an
incidental lesion diagnosed on the pathological examination
of the placenta, with no adverse effects onmother or infant, to
ametastaticmaternal or infantile disease.Due to the potential
fatal outcome of this entity if not treated [4, 6, 17, 18], careful
evaluation of both mother and infant after the diagnosis is
important. The real prevalence of the disease may actually
be higher than documented since it is not routine practice
to analyse all the placentas following each delivery. As the
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early diagnosis and appropriate management are essential,
the health providers should have an increased awareness of
the existence of these lesions and its manifestations.
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